PARP1 and ovarian carcinoma: To further study these effects in ovarian cancer, we stimulated the two murine ovarian cancer cell lines ID8-Trp53(−/−) and ID8-Trp53(−/−)Brca2(−/−) with the PARP inhibitor olaparib (10 μM) for 72 h and measured chemokine concentrations in the cell supernatants.